Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03331341
Title Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Washington
Indications

Hodgkin's lymphoma

Therapies

Dacarbazine + Doxorubicin + Pembrolizumab + Vinblastine

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.